Your browser is no longer supported. Please, upgrade your browser.
Cassava Sciences, Inc.
Index- P/E- EPS (ttm)-0.23 Insider Own5.80% Shs Outstand24.97M Perf Week56.45%
Market Cap449.41M Forward P/E81.06 EPS next Y0.16 Insider Trans15.65% Shs Float22.20M Perf Month63.56%
Income-5.20M PEG- EPS next Q-0.06 Inst Own26.50% Short Float24.09% Perf Quarter23.76%
Sales- P/S- EPS this Y56.70% Inst Trans30.91% Short Ratio1.68 Perf Half Y295.43%
Book/sh0.96 P/B13.51 EPS next Y176.20% ROA-20.90% Target Price- Perf Year57.21%
Cash/sh0.70 P/C18.65 EPS next 5Y- ROE-22.00% 52W Range1.63 - 12.99 Perf YTD90.18%
Dividend- P/FCF- EPS past 5Y32.60% ROI- 52W High-0.15% Beta1.45
Dividend %- Quick Ratio21.50 Sales past 5Y- Gross Margin- 52W Low695.71% ATR1.04
Employees9 Current Ratio21.50 Sales Q/Q- Oper. Margin- RSI (14)75.89 Volatility23.89% 10.80%
OptionableYes Debt/Eq0.00 EPS Q/Q-41.00% Profit Margin- Rel Volume1.68 Prev Close10.57
ShortableYes LT Debt/Eq0.00 EarningsNov 09 BMO Payout- Avg Volume3.18M Price12.97
Recom2.00 SMA2058.69% SMA5056.04% SMA200110.87% Volume5,334,201 Change22.71%
Oct-23-20Initiated Cantor Fitzgerald Overweight $24
Sep-23-20Upgrade H.C. Wainwright Neutral → Buy $20
May-18-20Downgrade H.C. Wainwright Buy → Neutral
May-15-20Downgrade Maxim Group Buy → Hold
Jan-10-20Reiterated Maxim Group Buy $3 → $12
Jan-04-21 08:30AM  
Dec-22-20 07:31AM  
Dec-07-20 08:19PM  
Nov-27-20 08:30AM  
Nov-19-20 10:08AM  
Nov-18-20 09:36AM  
Nov-16-20 10:06AM  
Nov-13-20 09:42AM  
Nov-12-20 04:48PM  
Nov-09-20 08:15AM  
Nov-04-20 08:15AM  
Oct-26-20 09:19AM  
Oct-23-20 10:15AM  
Oct-12-20 03:29PM  
Oct-07-20 09:35AM  
Sep-30-20 08:30AM  
Sep-28-20 07:44PM  
Sep-27-20 08:09AM  
Sep-22-20 10:04AM  
Sep-21-20 01:34PM  
Sep-20-20 06:53AM  
Sep-16-20 02:03PM  
Sep-14-20 12:44PM  
Sep-11-20 04:01PM  
Sep-09-20 08:15AM  
Sep-03-20 08:15AM  
Aug-24-20 08:15AM  
Aug-12-20 08:15AM  
Jul-14-20 08:44AM  
Jul-09-20 04:01PM  
Jun-16-20 08:15AM  
Jun-10-20 04:33PM  
Jun-03-20 08:15AM  
May-19-20 07:57PM  
May-15-20 02:05PM  
May-06-20 08:48AM  
May-03-20 07:30PM  
Apr-24-20 10:03AM  
Apr-23-20 08:15AM  
Apr-13-20 01:25PM  
Mar-26-20 08:15AM  
Mar-25-20 08:15AM  
Mar-19-20 08:15AM  
Mar-02-20 11:04AM  
Feb-11-20 08:15AM  
Jan-28-20 08:15AM  
Jan-10-20 09:33AM  
Jan-09-20 06:19AM  
Jan-08-20 11:23AM  
Jan-07-20 09:03AM  
Jan-06-20 05:05AM  
Jan-03-20 10:36AM  
Jan-02-20 10:19AM  
Dec-27-19 02:19PM  
Dec-10-19 07:42AM  
Dec-06-19 03:08PM  
Dec-05-19 09:00PM  
Dec-04-19 09:26AM  
Dec-01-19 09:30AM  
Nov-05-19 12:06PM  
Oct-29-19 08:15AM  
Oct-24-19 08:30AM  
Sep-20-19 10:02AM  
Sep-16-19 08:30AM  
Sep-09-19 02:42PM  
Sep-06-19 11:50AM  
Sep-03-19 08:30AM  
Aug-12-19 08:30AM  
Jul-08-19 02:51PM  
Jun-18-19 08:30AM  
May-28-19 08:29AM  
May-23-19 04:35PM  
May-16-19 10:36AM  
Apr-29-19 08:30AM  
Apr-15-19 08:30AM  
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARBIER REMIPresident and CEOSep 24Buy9.5910,00095,9001,078,855Sep 24 04:49 PM
ROBERTSON SANFORDDirectorSep 18Buy8.9236,281323,627912,623Sep 21 04:01 PM
Schoen EricChief Financial OfficerSep 17Buy7.042,00014,08027,300Sep 17 05:25 PM
Schoen EricChief Financial OfficerSep 17Buy7.0310,00070,30025,300Sep 17 05:25 PM
ROBERTSON SANFORDDirectorSep 17Buy6.98213,7191,491,759876,342Sep 17 05:15 PM